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Abstract
Increasing demand for human hematopoietic stem cells (HSCs) in clinical and research applications necessitates expansion
of HSCs in vitro. Before these cells can be used they must be carefully evaluated to assess their stem cell activity. Here, we
expanded cord blood CD34
+ CD133
+ cells in a defined medium containing angiopoietin like 5 and insulin-like growth factor
binding protein 2 and evaluated the cells for stem cell activity in NOD-SCID Il2rg
2/2 (NSG) mice by multi-lineage
engraftment, long term reconstitution, limiting dilution and serial reconstitution. The phenotype of expanded cells was
characterized by flow cytometry during the course of expansion and following engraftment in mice. We show that the SCID
repopulating activity resides in the CD34
+ CD133
+ fraction of expanded cells and that CD34
+ CD133
+ cell number correlates
with SCID repopulating activity before and after culture. The expanded cells mediate long-term hematopoiesis and serial
reconstitution in NSG mice. Furthermore, they efficiently reconstitute not only neonate but also adult NSG recipients,
generating human blood cell populations similar to those reported in mice reconstituted with uncultured human HSCs.
These findings suggest an expansion of long term HSCs in our culture and show that expression of CD34 and CD133 serves
as a marker for HSC activity in human cord blood cell cultures. The ability to expand human HSCs in vitro should facilitate
clinical use of HSCs and large-scale construction of humanized mice from the same donor for research applications.
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Introduction
Human hematopoietic stem cells (HSCs) were the first clinically
important class of stem cells and are now frequently used in
autologous and heterologous transplantation to treat a range of
hematologic malignancies and congenital immunological defects
[1,2]. HSCs for transplantation are usually isolated from umbilical
cord blood, bone marrow (BM), or mobilized adult peripheral
blood [3,4]. In the case of cord blood, where sample sizes are
small, adults often receive cells from two donors to ensure infusion
of sufficient numbers of HSCs. The chronic shortage of well
matched HSCs has stimulated significant interest in expanding
HSCs in vitro for transplantation.
There are three major challenges in expanding human HSCs
for clinical and preclinical applications. First, efficient methods are
needed for expanding HSCs rather than allowing cells to
proliferate, differentiate and eventually die. Over the last two
decades, quite a few HSC expansion protocols have been
reported. The earlier studies explored the use of stromal cells as
‘feeders’ [5]. More recently feeder-free cultures using defined
media and recombinant growth factors were used because of their
simplicity and increasing evidence of efficacy [6]. Second, the
expanded cells have to be characterized and their stem cell activity
quantified. The best evaluations require engraftment into
immunodeficient mice, such as NOD-scid mice, and assaying for
long-term multi-lineage reconstitution and serial reconstitution
[7]. Recently, better mouse strains, such as NOD-scid Il2rg
2/2
(NSG) mice, that lack their own T cells, B cells and natural killer
(NK) cells [8,9,10,11] have been used because these mice support
both long-term and much more robust lymphoid and myeloid cell
reconstitution, resulting in mice with robust enough grafts to begin
studying the human cells (humanized mice). Third, there is a need
for surrogate markers for rapid assessment of HSC expansion.
This is because the functional verification by engrafting HSCs in
immunodeficient mice takes months. The availability of surrogate
markers that can quickly assess the quality of expanded cells make
it possible to use the expanded cells immediately without freezing
the cells and waiting for the in vivo results. By a combination of
fractionation and in vivo reconstitution, studies have identified cell
surface markers that differentiate freshly isolated HSCs from more
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identification of HSCs following expansion is complicated by
changes in both surface marker expression and stem cell activity
during the culture. To our knowledge, surface markers that closely
correlate with SCID repopulating activity both before and after
HSC culture have not been reported.
We have previously shown that stem cell factor (SCF),
thrombopoietin (TPO) and fibroblast growth factor 1 (FGF1) in
combination with angiopoietin-like proteins or insulin-like growth
factor binding protein 2 (IGFBP2) support a significant expansion
of murine HSCs in a feeder-cell-free, serum-free culture [12,13].
Further study demonstrated that the combination of these five
growth factors also supports expansion of human cord blood
CD34
+ CD133
+ cells. When the expanded human cells were
tested for the ability to reconstitute NOD-scid recipient mice, an
approximately 20-fold expansion of SCID repopulating cells
(SRCs) was obtained during a ten-day culture [14].
In this report, we expand cord blood CD34
+ CD133
+ cells in
the defined medium described above and assess the cell surface
phenotype during the course of the culture and the stem cell
activity of resulting cells in NSG recipient mice. Specifically, we
address three questions. Firstly, what cell surface phenotype
correlates with HSC activity before and after in vitro expansion?
Secondly, does the expansion of SRCs observed in NOD-SCID
mice occur in NSG mice and if so does this expansion correlate
with an expansion of HSCs? Lastly, can the expanded cells be used
for large-scale construction of humanized mice for preclinical
studies?
Materials and Methods
Ethics Statement
All research with human samples and mice was performed in
compliance with the institutional guidelines, the World Medical
Association’s Decleration of Helsinki and the US Department of
Health and Human Services Guide for the Care and use of
Laboratory Animals. The MIT committee on the use of humans as
experimental subjects (MIT COUHES) granted the research a
waiver as all human samples (umbilical cord blood, normally
disposed of as medical waste) were collected anonymously with
parental consent by a 3rd party and purchased from that party for
the research. The MIT committee on animal care (MIT CAC)
approved the research as part of animal protocol 0310-027-13.
Cell isolation and culture
Purified CD133
+ human umbilical cord HSCs were purchased
from AllCells (California) or National Disease Research Inter-
change (NDRI). Alternatively, CD133
+ cells were purified from
fresh umbilical cord blood purchased from NDRI. Umbilical cord
blood was centrifuged through ficoll-hypaque, and purified using a
combination of PE-conjugated anti-CD133 antibody (Miltenyi)
and PE positive selection kit (Stem Cell Technologies) according to
the manufacturers’ protocols. Human HSCs were cultured as
reported previously [14], using StemSpan (Stem Cell Technolo-
gies, Vancouver) supplemented with human growth factors:
10 ng/ml FGF-1 (Invitrogen), 20 ng/ml SCF, 10 ng/ml TPO,
100 ng/ml IGFBP2 (all R&D systems), 500 ng/ml Angiopoietin
like 5 (Abnova, Taiwan), 10 micrograms/ml of heparin and 16
penicillin/streptomycin (Mediatech, Manassas, VA). Briefly,
CD133
+ cells were plated at 50,000 cells/ml in growth factor-
supplemented StemSpan in a 96 well round bottomed plate, at
200 ml/well. Cells were transferred to a 6 well plate 2–3 days later
and more media was added to keep cell density below 200,000/ml
one day after the transfer. Cells were supplemented with
additional media 2–3 days later in order to dilute them to
700,000 cells/ml. Cells were then allowed to expand until the end
of the 10 day culture.
Mice
NOD-SCID Il2rg
2/2 mice were obtained from the Jackson
Laboratory and bred in the animal facility at Massachusetts
Institute of Technology. Neonate and adult mice were sub-lethally
irradiated with 100 or 270 rads, respectively, using a Gamma Cell
40 Caesium source, as reported previously [15]. Expanded, re-
isolated or unexpanded human HSCs were transferred into
neonates by intracardiac injection within the first 48 hours after
birth or into adult (2–4 month old) mice by tail vein injection.
Tissue preparation, antibodies and flow cytometry
At various time points following injection of NSG recipients with
human HSCs, mice were euthanized by CO2 asphyxiation and
blood, bone marrow, spleen, lymph nodes and thymus were
harvested.The spleensweredigested by collagenaseD at 37 degrees
for 1 hour and the bone marrow were flushed using syringes with a
27 gauge needle. All organs were then disrupted by grinding
between frosted glass cover slips and single cell suspensions were
prepared. Samples were lysed of red blood cells and cells were
counted. FITC, PE, PerCP/cy5.5, APC, PE/Cy7 or APC/Cy7
conjugated antibodies, including human CD3, CD4, CD8, CD10,
CD11c, CD14, CD15, CD16, CD19, CD20, CD33, CD34, CD41,
CD45, CD56, CD69, CD71, CD209, CD235ab, HLA-DR, and
murine CD45.1, were from Biolegend. Anti-CD133 antibody was
from Miltenyi. Cells were stained with appropriate combination of
antibodies and then analyzed on FACScalibur, FACS-Canto or
LSR II flow cytometers (Beckton Dickinson) in the MIT Koch
Institute flow cytometry core facility. Dead cells were excluded from
analysis by DAPI or propidium iodide staining.
Limiting dilution assay
In order to calculate how many cells within a sample are needed
to minimally repopulate a mouse (a repopulating unit) small
numbers of cells (5000, 1000, or 400) were injected into sub-
lethally irradiated NSG mice. Three to 4 months after injection,
bone marrow was harvested and analyzed for the level of human
cell reconstitution. A repopulating unit is calculated as the number
of cells at which 37% of injections fail to give a minimal human
cell engraftment in bone marrow. Based on Fishers exact test the
thresholds selected and number of events collected (.100,000/
mouse) give chance of false positives as less than 1e-9/mouse.
Chimerism
Chimerism, or the level of human leukocyte reconstitution, was
calculated as follows:
Chimerism=%CD45
+ human cell/(%CD45
+ human cell+
%CD45
+ mouse cell).
Statistical analysis
Statistical analysis was carried out using Graphpad Prism 5.
Two way ANOVA was used to compare series and the two tailed
T test with Welch’s correction were used for pairwise comparisons.
Results
Expansion of CD34
+ CD133
+ cells correlates with SCID-
repopulating activity
In order to assess how well the cultured progeny of CD133
+
cells reconstitute NSG recipient mice small numbers of CD133
+
Expanded HSCs Efficiently Engraft NSG Mice
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were injected into sub-lethally irradiated neonate recipients.
Human CD133
+ cells were purified from cord blood and either
injected into NSG mice or cultured for 10 days with SCF, TPO,
FGF, IGFBP2 and angiopoietin-like 5 as previously described [14]
and then injected into NSG mice. Three months later, mice were
analyzed for human cell reconstitution in the bone marrow by
staining for human CD45 and mouse CD45.1 followed by flow
cytometry. In order to avoid any potential bias in the analysis, we
employed two cutoffs of 0.1% and 0.5% of human cell
reconstitution in the bone marrow that have been commonly
used in recent publications [14,16]. We determined the frequency
of SRCs among total input cells using Poisson statistics for both
cultured and uncultured cells at both thresholds (Figure 1A). At the
0.1% cutoff 653 input cells were needed for minimal repopulation
and just 33 cells after 10 days of culture, an ,20 fold increase in
SCID repopulating activity following culture. At the 0.5%
threshold 3598 uncultured cells were needed to minimally
repopulate and the progeny of just 172 cells after 10 days of
culture, an ,21 fold increase in SCID repopulating activity. These
results are similar to the ,20 fold expansion of SCID repopulating
activity that we reported for the expanded cells in NOD-SCID
recipient mice.
Next we assessed the cell surface phenotype before and after
culture. Starting populations of cells were 80–99% CD133
+ with
all of these cells also expressing CD34 (Figure 1B). Following 10
days of culture 13–34% of the expanded cells expressed CD34
and CD133 concurrently (Figure 1B). We reasoned that CD34
+
CD133
+ double positive cells might also identify the HSC-
containing population after culture. Upon assessing the total
number of these cells at the end of 10 day culture, we found that
CD34
+ CD133
+ number increased 14–30 fold (mean 21 fold)
although the increase in total cell number varied from 66–160
fold (Mean 110 fold). Using a single marker to identify the stem/
progenitor population resulted in much more variable counts as
CD133
+ cell number expanded 10–70 fold (mean 28 fold) and
CD34
+ cells expanded 8–80 fold (mean 22 fold). In fact, almost
all cells in the culture were CD34
dim or CD34
+ on day 10 (data
not shown), making it difficult to quantify them. In all cases
CD34
+ CD133
+ cell number in the culture correlated tightly with
SCID repopulating activity in mice. We therefore used the
double marker CD34
+ CD133
+ as it gave a robust identification
of the SCID repopulating cells whereas the single markers varied
more from culture to culture due to poor separation in some
cultures.
To assess the capacity of CD34
+ CD133
+ cell number to
predict SCID repopulating activity before and after culture, 400,
1000 and 5000 uncultured CD34
+ CD133
+ cells and the total
cultured cells containing 400, 1000 and 5000 CD34
+ CD133
+
cells were injected into neonate NSG mice and the chimerism in
the bone marrow was assessed 12 weeks after injection. Similar
levels of human cell reconstitution were observed at the three
corresponding CD34
+ CD133
+ cell levels (Figure 1C). Further-
more, we purified CD34
+ CD133
+ cells from day 10 cultures by
magnetic enrichment and injected these cells (1610
5 per
recipient) or total cultured cells containing the same number of
CD34
+ CD133
+ cells into NSG mice. Twelve weeks after transfer
chimerism was assessed in the peripheral blood. Both groups of
mice showed similar levels of long term reconstitution (Figure 1D).
In contrast, when 30 million cultured cells depleted of CD34
+
CD133
+ cells were injected into sub-lethally irradiated adult
mice, no reconstitution was detected in the peripheral blood (data
not shown). To eliminate the possibility that non-CD34
+ CD133
+
cells while not able to directly engraft NSG mice might promote
or inhibit engraftment of CD34
+ CD133
+ cells, following
expansion we transferred 300 and 1000 purified CD34
+
CD133
+ cells or total cells containing 300 and 1000 CD34
+
CD133
+ cells into sub-lethally irradiated adult NSG mice. The
mice were sacrificed 8 weeks later and assessed for minimal
reconstitution in the bone marrow. As shown in Figure 1E, both
purified and unpurified CD34
+ CD133
+ cells had similar
repopulating activity regardless of the presence of other cells
from the culture. These results show that the SCID repopulating
activity resides in the CD34
+ CD133
+ population and is
comparable before and after culture.
Expanded CD34
+ CD133
+ cells maintain capacity for long
term engraftment and serial reconstitution in NSG mice
Human HSCs are characterized by the ability to support long-
term (6 month or longer) as well as serial reconstitution in
immune-deficient mice. As sublethally irradiated NSG mice do not
develop lethal thymomas as NOD-scid mice do, we determined
whether the SCID repopulating cells from the 10 day culture
contain long-term HSCs. Thus, 2.5–5610
5 cultured CD34
+
CD133
+ cells were transferred into sub-lethally irradiated adult
NSG mice. Three and six month later, peripheral blood
mononuclear cells (PBMC) of recipient mice were analyzed for
the presence of human CD45
+ cells. As shown in Figure 2A the
chimerism of these mice was statistically indistinguishable at 3 and
6 months post reconstitution. Furthermore, the number and
lineage of human cells in the bone marrow, spleen, and thymus
were similar between mice that were reconstituted for 3–4 months
and for 6–7 months (Figures 3, 4 and data not shown). In addition,
primary reconstituted NSG mice were sacrificed 3–6 months after
the initial transfer and human cells were enriched either by
depleting cells expressing mouse CD45 or by positive selection for
human CD34
+ cells. Each secondary recipient mouse was
reconstituted with a fraction of enriched cells equivalent to those
from 1 femur. Three months later, the secondary recipients were
assessed for human cell chimerism in the bone marrow and spleen.
When transferred human cells were depleted of mouse CD45
+
cells, high levels (1.7–11.5%) of secondary reconstitution were
observed (Figure 2 and Table 1), possibly reflecting the presence of
human precursor cells in the transferred population rather than
just stem cells. When transferred human cells were CD34-selected,
significant levels of reconstitution (0.12–0.88%) were observed in
all secondary recipients in three separate experiments (Table 1).
Considering that 0.1% chimerism in the bone marrow is generally
considered as positive secondary reconstitution with human HSCs,
these results suggest that expanded CD34
+ CD133
+ cells contain
long-term HSCs.
Expanded CD34
+ CD133
+ cells give robust reconstitution
in both neonate and adult recipients
The significant expansion of CD34
+ CD133
+ cells makes it
possible to reconstitute large numbers of adult mice from a single
cord. To assess the capacity of expanded CD34
+ CD133
+ cells for
reconstitution of adult recipients, increasing numbers of expanded
cells were injected into sub-lethally irradiated adult NSG mice.
The percentage of human cells (chimerism) in the peripheral blood
was lower when 0.5610
5 CD34
+ CD133
+ cells were injected
(Figure 3A). However, chimerism reached 40–60% when 2.5610
5
to 5610
5 CD34
+ CD133
+ cells were injected. For these reasons,
2.5–5610
5 CD34
+ CD133
+ cells were injected into adult
recipients in the following studies.
We also compared reconstitution in the bone marrow and
spleen of adult and neonate recipients injected with expanded or
Expanded HSCs Efficiently Engraft NSG Mice
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+ CD133
+ cells are SCID repopulating cells. (A) Limiting dilution analysis comparing cultured (squares) vs.
uncultured (circles) cells for SRC frequency. CD133
+ cord blood cells (5,000, 1,000 and 400) and their cultured progeny were injected into sub-lethally
irradiated neonate recipients. Recipients were analyzed for human cell reconstitution in the bone marrow by staining for human CD45 and mouse
CD45 followed by flow cytometry. SRC frequencies calculated by Poisson statistics are shown for each population based on number of input CD34
+
CD133
+ cells. Values for a 0.5% cutoff (top) and 0.1% cutoff (bottom) are shown. (B) Representative CD34 versus CD133 staining profiles of purified
human HSCs at the start of in vitro expansion and cells after culture for 10 days. The number indicates percentage of CD34
+ CD133
+ cells in the gated
region. (C) Comparison of bone marrow chimerism (human CD45 vs. mouse CD45.1) in sub-lethally irradiated neonate NSG recipients injected with
5000, 1000 and 400 cultured or uncultured CD34
+ CD133
+ cells. Horizontal bars show the mean, each symbol is an individual mouse. Two tail ANOVA
testing shows no significant differences between data sets (p=0.23). (D) Comparison of reconstitution in neonate NSG recipients transferred with
100,000 purified, cultured CD34
+ CD133
+ cells or total cultured cells (unpurified) containing 100,000 CD34
+ CD133
+ cells. Peripheral blood
mononuclear cells were analyzed for human and mouse CD45 12 weeks after transfer. Mean 6 SD is shown with 7 mice per group. (E) Limiting
dilution analysis comparing purified (circles) and unpurified (squares) CD34
+ CD133
+ cells for SRC frequency. 300 and 1000 purified CD34
+ CD133
+
cells or total cells containing 300 and 1000 CD34
+ CD133
+ cells were transferred into sub-lethally irradiated adult NSG mice. Recipients were analyzed
for human cell reconstitution in the bone marrow 8 weeks later by flow cytometry. Frequencies calculated using Poisson statistics are shown for each
population based on the number of CD34
+ CD133
+ cells. All limiting dilutions represent 6–10 mice per data point and are single cultures
representative of at least 2 independent experiments.
doi:10.1371/journal.pone.0018382.g001
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bone marrow (62–78%) of neonate recipients injected with
expanded or unexpanded CD34
+ CD133
+ cells (Figure 3B),
consistent with a previous report [8]. The chimerism in the spleen
of neonate recipients injected with expanded or unexpanded
CD34
+ CD133
+ cells were also similar (,80%, data not shown),
though these values were slightly higher than those reported by
Ishikawa et al. (,55%) [8]. Surprisingly, the chimerism was
,90% in both the bone marrow and spleen of adult recipients
when 2.5–5610
5 CD34
+ CD133
+ cells were injected (Figure 3B
and Table 2). Together, these results suggest that expanded
CD34
+ CD133
+ cells are capable of robust reconstitution in both
neonate and adult recipients.
Human cell reconstitution in adult NSG mice
reconstituted with expanded CD34
+ CD133
+ cells
We further characterized in detail the development of human
blood lineage cells in adult NSG recipients injected with expanded
CD34
+ CD133
+ cells. We assessed whether CD34
+ CD133
+ cells
were present in the reconstituted mice. On average, 1% of the
human cells in the bone marrow were CD34
+ and CD133
+
(Figure 2B and Table 2). We assessed the presence of various
myeloid lineage cells, erythrocytes and platelets in the bone
marrow and peripheral blood. The level of CD235ab
+ human
erythrocytes was low in the peripheral blood (,0.05%) and slightly
higher in the bone marrow (,2%) (Figure 4A and F, Table 2),
consistent with a previous report [8]. The level of CD41
+ human
platelets was also low in peripheral blood (,0.4%) and higher in
the bone marrow (,1.2%) (Figure 4A and F, Table 2). A
significant population of CD33
+ CD14
+ human myelomonocytes
was detected in both bone marrow and spleen (Figure 4 C and H,
Table 2), although the level of CD14 expression was significantly
lower on those in the spleen than on those in the bone marrow.
The pro-inflammatory subset of monocytes is known to express
lower levels of CD14 and is CD38 negative [17]. A low level of
CD209
+ CD11c
+ human dendritic cells was seen in the bone
Figure 2. Expanded CD34
+ CD133
+ cells contain long-term HSCs. (A) Comparison of chimerism in peripheral blood at 3–4 and 6–7 months
post reconstitution. Sub lethally irradiated adult NSG mice were injected with CD34
+ CD133
+ cells (2.5–5610
5 per mouse) 3–4 and 6–7 months post
injection PBMCs were stained for human and mouse CD45. Mean 6 SD is shown with 6 mice per group. (B) Presence of human CD34
+ CD133
+ cells in
the bone marrow of reconstituted mice. Cells from the bone marrow of primary recipient mice 3–4 month after reconstitution were analyzed for
human CD45, CD34 and CD133. Representative CD34 versus CD133 staining profiles are shown for human CD45
+ cells. The number indicates the
percentage of cells in the gated region. Serial reconstitution. Single cell suspension was prepared from the bone marrow of the primary recipient
mice 14–28 weeks after engraftment. Human cells were enriched by depleting cells expressing mouse CD45 or by positive selection for human CD34
+
cells by magnetic sorting. An equivalent of one femur’s worth of enriched human cells was transferred into one sub-lethally irradiated secondary
neonate or adult recipient. Twelve weeks later, cells from the spleen and bone marrow of secondary recipient mice were analyzed for human and
mouse CD45. Human CD45 versus mouse CD45 staining profiles are shown for the secondary mouse with the highest human chimerism (n=10, see
Table 1).
doi:10.1371/journal.pone.0018382.g002
Figure 3. Expanded CD34
+ CD133
+ cells give robust reconsti-
tution in both neonate and adult recipients. (A) Comparison of
reconstitution levels in mice injected with different numbers of
expanded cells. Sub-lethally irradiated adult NSG recipients were
injected with cultured cells containing 0.5610
5, 2.5610
5 or 5610
5
CD34
+ CD133
+ cells. Eight weeks later, PBMCs were analyzed for human
and mouse CD45 expression. Mean 6 SD is shown, n=6–8 per group.
(B) Comparison of reconstitution levels in the bone marrow of neonate
and adult recipients. Sub-lethally irradiated adult NSG recipients were
injected with expanded cells containing 2.5610
5 CD34
+ CD133
+ cells.
Sub-lethally irradiated neonates were injected with 1610
5 unexpanded
or expanded CD34
+ CD133
+ cells. Twelve to sixteen week later, bone
marrow was analyzed for human and mouse CD45 expression. Mean 6
SD is shown, n=4–6 per group.
doi:10.1371/journal.pone.0018382.g003
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the spleen (Figure 4D and I, Table 2). CD15
+ human granulocytes
and CD56
+ human NK cells were also more abundant in the bone
marrow than in the spleen (Figure 4F and J, Table 2).
Consistent with previous reports, the majority of human cells
present in the reconstituted mice were lymphocytes. CD19
+ B cells
accounted for ,3/4 of the human cells in the spleen and ,2/3 of
the human cells in the bone marrow (Figure 4K and L).
Approximately 75% of the CD19
+ cells in the spleen were
IgM
+IgD
+ naı ¨ve B cells. In the bone marrow, approximately 65%
of the CD19
+ cells were IgM
2IgD
2 CD10
+ pro-B or pre-B cells
(Figure 4L). Based on CD34 and CD10 expression, approximately
12% were pro-B cells and 50% were pre-B cells (Table 2). In
addition, only ,4% of human CD19
+ cells in the bone marrow
were naı ¨ve B cells.
Compared to B cell reconstitution, the level of T cell
reconstitution in the adult NSG mice injected with expanded
CD34
+ CD133
+ cells was fairly low (Figure 4M–O, Table 2). In
the thymus, most of thymocytes were of human origin and were
CD4
+ and CD8
+, with small proportions of CD4
2 CD8
2 or CD4
+
or CD8
+ cells, suggesting normal development of human T cells in
the thymus. In the spleen, ,5% of human cells were CD3
+ T cells.
The ratio of CD4 to CD8 T cells was 2 to 1, similar to that in
humans.
Figure 4. Multi-lineage reconstitution in adult NSG mice. Sub-lethally irradiated NSG adults were injected with 2.5–5610
5 expanded CD34
+
CD133
+ cells. Cells in the bone marrow (A–E, L), blood (F, O), thymus (M) and spleen (G–J, K, N) were analyzed by flow cytometry 12 weeks after
reconstitution. Shows are staining profiles for erythrocytes (CD235ab
+) and platelets (CD41
+) (A and F), total leukocytes (human CD45
+) (B and G),
myelomonocytes (CD14
+ CD33
+) (C and H), dendritic cells (CD11c
+ CD209
+) (D and I), granulocytes (CD15
+) and natural killer cells (CD56
+) (E and J),
B cell stages (proB - CD34
+ CD10
+, immature - CD10
+, mature - IgM
+ IgD
+) (K and L), T cell precursors (double negative, double positive and single
positive) (M) and mature T cells (CD45
+ CD3
+ expressing either CD4 or CD8) (N and O). The numbers indicate percentages of cells in the gated region.
Representative data from one of at least 5 mice are shown. All cells shown are gated on live human cells (FSC/SSC/live/CD45
+) except A, F (FSC/SSC
only) B, G (FSC/SSC/live) and the IgM vs IgG stains (FSC/SSC/live/CD45
+/CD19
+). Summaries of human cell characterization can also be found in
Table 2.
doi:10.1371/journal.pone.0018382.g004
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+
CD133
+ cells are capable of giving rise to different lineages of
human blood cells in the adult NSG mice.
Discussion
We have previously reported expansion of SCID repopulating
activity of human cord blood-derived CD133
+ cells in a medium
containing angiopoietin-like protein 5, IGFBP2, SCF, TPO and
FGF1 [14]. Here we show that the SCID repopulating activity is
correlated with the presence of CD34
+ CD133
+ cells in culture.
Expansion of CD34
+ CD133
+ cells also expands cells capable of
mediating long-term multi-lineage hematopoiesis and serial
reconstitution in NSG mice. In addition, we found that
expanded CD34
+ CD133
+ cells give robust reconstitution in
the bone marrow, spleen and blood of adult NSG recipients.
Here we discuss these observations and highlight their potential
applications.
CD34
+ CD133
+ cells measure expansion of hematopoietic
stem cells
Many cell surface markers have been identified that define
populations enriched for freshly isolated human HSCs, including
the CD133
+ subset of CD34
+ hematopoietic cells first identified in
1997 by Yin et al. [18]. However much less is known about
whether these marker sets retain their predictive value after culture
[19]. Total cell number and fold increase in CD34
+ cells have
most commonly been used, and while these correlate with
expansion of SRCs the ratio of SRCs/cell changes dramatically
during culture. Recently CD34 expression was used in a chemical
library screen to identify StemReginin1 as a chemical mediator of
HSC expansion [20]. However, in this case as in many others a
dramatic (.1100 fold) expansion of CD34 expressing cells led to
only a modest ,16 fold increase in SRC number. Here we report
that the use of both CD34 and CD133 led to a much better
correlation with SRC number both before and after culture
(Figure 1). Our culture method did not lead to nearly such
dramatic CD34
+ cell number increases, perhaps due to the
absence of growth factors such as Flt-3 ligand that normally
support committed progenitors expressing CD34. We did notice
greater variability in CD34
+ cell expansion, a trend similar to that
reported by Delaney et al. who saw CD34
+ cell number expansion
ranging from 36–688 fold with an increase in long term SRC
Table 1. Summary of secondary reconstitutions in NSG mice.
Exp # HSC Origin
Primary
Recipient
Length of Primary
Reconstitution (wks)
Secondary
Recipients
Method of HSC
Enrichment Chimerism (%)
#CD34+
injected
1 Cord #1 Adult 14 Adult CD45.1 depleted 19.4 200,000
1 Cord #1 Adult 14 Adult CD45.1 depleted 0.4 200,000
2 Cord #1 Adult 28 pup CD45.1 depleted 2.05 80,000
2 Cord #1 Adult 28 pup CD45.1 depleted 1.45 80,000
3 Cord #2 pup 14 Adult CD34 Enrich 0.24 90,000
3 Cord #2 pup 14 Adult CD34 Enrich 0.23 90,000
4 Cord #3 Adult 16 Adult CD34 Enrich 0.59 50,000
4 Cord #3 Adult 16 Adult CD34 Enrich 0.88 50,000
4 Cord #3 Adult 16 Adult CD34 Enrich 0.13 50,000
5 Cord #4 Adult 16 Adult CD34 Enrich 0.12 n.d.
2.5–5610
5 expanded CD34
+ CD133
+ cells were transferred into the primary neonate or adult NSG recipients. 14–28 weeks after transfer, single cell suspension was
prepared from the bone marrow of recipient mice. Human cells were isolated by either depleting mouse CD45
+ cells or enriching for human CD34
+ cells and then
transferred into secondary neonate or adult recipients. Each secondary recipient received an equivalent of one femur’s worth of enriched human cells. The numbers of
CD34
+ cells were calculated and shown to the nearest 10,000 cells. n.d. – not determined. 12 weeks after secondary transfer, chimerism was assessed in the bone
marrow by staining for human and mouse CD45.
doi:10.1371/journal.pone.0018382.t001
Table 2. Summary of reconstitution of adult NSG mice
injected with 2.5–5610
5 expanded CD34
+CD133
+cells.
Cell Type Markers Blood Spleen
Bone
Marrow
%S D %S D %S D
Human
Leukocyte
CD45+ 56.7 21.7 92.3 2.3 89.0 5.3
HSCs CD34
+CD133
+ N.D. - N.D. - 1.0 0.3
Erythrocyte CD235ab
+ 0.05 0.01 N.D. - 1.1 0.9
Platelet CD41
+ 0.4 0.7 N.D. - 1.2 1.1
Myelomonocyte CD14
+CD33
+ 4.4 1.1 1.3 0.0 5.3 1.3
Dendritic Cell CD11c
+CD209
+ N.D. - 0.1 0.05 0.3 0.1
Gruanulocyte CD15
+ 3.9 1.0 1.6 0.0 7.0 3.6
NK cell CD56
+ 1.6 0.4 3.5 1.0 2.6 2.7
Pro B Cell CD34
+CD19
+CD20
2 N.D. - 1.0 0.5 12.5 1.6
Pre B Cell CD34
2CD19
+
CD20
+IgM
2
N.D. - 9.9 4.6 49.5 2.9
Immature B Cell CD19
+IgM
+CD10
+ N.D. - 60.5 1.7 18.8 2.9
Mature B Cell CD19
+IgM
+CD10
2 N.D. - 15.6 3.7 3.7 1.1
CD4 T Cell CD3
+CD4
+ 3.1 0.9 3.4 1.2 0.6 0.7
CD8 T Cell CD3
+CD8
+ 1.6 0.5 2.7 1.0 0.3 0.5
Circulating B Cell IgM
+CD19
+ 76.6 3.356 N.D. - N.D. -
Data are a compilation of 24 mice. Each stain was performed on a minimum of 4
mice and all stains were performed on mice derived from at least two unrelated
cords. All percentage calculations are based on the following gated groups:
human leukocytes on total live (DAPI/PI negative) human or mouse CD45
+ cells,
erythrocytes and platelets on FSC versus SSC gate, and all other groups on live
human CD45
+ cells. Shown are mean percentage and SD of specific cell types in
blood, spleen and bone marrow. ND, not determined.
doi:10.1371/journal.pone.0018382.t002
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StemReginin 1, surrogate markers for monitoring HSC expansion
are extremely valuable for screening compounds that stimulate
HSC expansion and could be key to quality control in HSC
transplantation.
Angiopoietin like 5 and IGFBP2 mediate expansion of
human HSCs
The stable long-term multi-lineage reconstitution, as well as
serial reconstitution with expanded CD34
+ CD133
+ cells, which
could be assessed in NSG mice but not NOD-scid mice, suggests
that these cells contain an expanded subpopulation of long term
HSCs. This expanded population also possesses the same SCID
repopulating activity as unexpanded CD34
+ CD133
+ cells.
Limiting dilution analysis showed that similar numbers of
expanded and unexpanded CD34
+ CD133
+ cells were required
to minimally repopulate NSG recipients. These results further
support the idea that the angiopoietin-like family of proteins and
IGFBP2 are important in promoting expansion of both murine
and human HSCs in culture [12,13,14]. It is likely that these
growth factors mediate HSC survival in vivo although to date no
direct testing of this hypothesis, for example with inducible
knockouts, has been conducted. The recent clinical trial reported
by Delaney et al. demonstrated the short-term clinical benefits of
using two cord blood samples one of which was expanded to
reduce the period of neutropenia following transplantation [21].
However, while the cultured cord blood dominated short-term
engraftment, the uncultured cord blood dominated long-term
engraftment. This suggests that as yet the optimal culture and
transplantation conditions have not been found and other culture
systems showing promising results in xenotransplantation studies
should be tested in similar clinical trials. The work reported here in
combination with the work previously reported by Zhang et al.
suggests that the cocktail of SCF, TPO, FGF, IGFBP2 and
Angptl5 should be one of those investigated clinically.
Reconstitution of adult NSG mice with expanded CD34
+
CD133
+ cells offers an efficient way to construct
humanized mice
Previously, two studies investigated reconstitution of adult NSG
mice with purified CD34
+ cells. In the study by Shultz et al, sub-
lethally irradiated adult NSG mice were transferred with
mobilized peripheral blood CD34
+ cells. Hayakawa et al. used
busulfan conditioning rather than sub-lethal irradiation and both
mobilized peripheral blood CD34
+ cells and cord blood CD34
+
cells were used [22,23]. In these studies ,50% reconstitution in
blood and ,90% in bone marrow were achieved using 2 million
fresh cord blood CD34
+ cells. This is similar to the levels of
reconstitution we achieved with the cultured progeny of 12–25,000
CD34
+CD133
+ cells. Where CD34
+ cells derived from adults were
used much lower levels of reconstitution were achieved, possibly
reflecting reduced HSC potential with increasing donor age.
Giassi et al. also investigated reconstitution with cultured cord
blood CD34
+ cells [15]. In their study, only ,5% reconstitution in
the peripheral blood and ,25% reconstitution in the bone
marrow were observed following injection of 1610
6 cultured cells
derived from ,27,000 cord blood CD34
+ cells per recipient. We
injected the progeny of a similar small number of cells (12–25,000
CD34
+CD133
+ cells) and achieved ,50% reconstitution in the
blood and ,90% in the bone marrow. This far more robust
reconstitution is likely due to the difference in ex vivo culture. Our
culture method is, to our knowledge, the first method examined to
date that generates large numbers robustly reconstituted human-
ized mice from small numbers of purified HSCs. This technology
is valuable to increase cohort sizes of humanized mice without
having to use many unrelated donors. The option of using adult
NSG mice also eliminates the technical hurdles imposed by
reconstitution of neonates making experiments easier to conduct.
We also characterized the development of various human blood
lineage cells in NSG recipients following transfer with expanded
CD34
+ CD133
+ cells. Human myeloid lineage cells, including
erythrocytes, platelets, monocytes, granulocytes and dendritic cells,
were detected at low levels in recipient mice, similar to those
observed in NSG recipients injected with unexpanded HSCs
reported by Shultz et al. and Hayakawa et al. [8,22,23]. The poor
myeloid cell reconstitution is likely due to deficiencies in human
cytokines as described in the literature [24,25] rather than any loss
of potential due to in vitro culture. In contrast, the lymphoid lineage
is robustly reconstituted. Large numbers of B cell precursors are
present in the bone marrow and the majority of B cells in the
spleen are naı ¨ve B cells (CD19
+IgM
+IgD
+). However, many of
these cells still express CD10 indicating they may not be fully
mature [26]. The latter observation is consistent with the report by
Ishikawa et al. showing that many CD19
+ cells in the spleen
expressed IgM but not IgD and that the majority of cells still
express CD10 [8]. Compared to B cells, T cell reconstitution is
more modest although the ratio of CD4 to CD8 and proportion of
different thymocyte populations indicates normal T cell develop-
ment. The low number of T cells is probably due to the reduced
response of human T cells and their precursors to the mouse
survival cytokines IL-7 and IL-15 in NSG recipients [24].
Nevertheless, the level of T cell reconstitution in our study was
significantly better than that reported by both Hayakawa et al.
(0.3%) and Giassi et al., who did not detect any T cells without
treating mice with TNF. It seems that HSCs expanded with our
culture conditions favor lymphoid cell development in NSG mice,
in a manner reminiscent of uncultured cells, whereas HSCs
cultured with the method used by Giassi et al. favor the
development of myeloid cells possibly due to the presence of
Flt3-L, which supports the survival and expansion of myeloid
progenitor cells [27].
In summary, we have demonstrated that the SCID repopulating
cells we previously reported [14] contain a ,206 expanded
population of HSCs. In addition, we have provided evidence that
surface expression of both CD34 and CD133 correlates with the in
vivo repopulating activity of the expanded HSCs. Finally, we have
shown that reconstitution of adult NSG mice with expanded HSCs
provides a powerful method to generate large numbers of
humanized mice using HSCs from a single cord blood sample.
The method reported here represents an important step towards
building a generally applicable humanized mouse model for
research and offers an improved and robust culture method for
expanding human HSCs for clinical follow-up.
Acknowledgments
We thank Drs. Herman N. Eisen, Cheng-Cheng Zhang and Glenn Paradis
for discussion and/or critical review of the manuscript.
Author Contributions
Conceived and designed the experiments: ACD MK HL JC. Performed
the experiments: ACD MK IL BPI MF. Analyzed the data: ACD MK IL
HL JC. Wrote the paper: ACD IL HL JC.
Expanded HSCs Efficiently Engraft NSG Mice
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18382References
1. Pecora AL (2001) Progress in clinical application of use of progenitor cells
expanded with hematopoietic growth factors. Curr Opin Hematol 8: 142–148.
2. Robinson S, Niu T, de Lima M, Ng J, Yang H, et al. (2005) Ex vivo expansion of
umbilical cord blood. Cytotherapy 7: 243–250.
3. Dieterlen-Lievre F (2007) Emergence of haematopoietic stem cells during
development. C R Biol 330: 504–509.
4. Orkin SH, Zon LI (2008) Hematopoiesis: an evolving paradigm for stem cell
biology. Cell 132: 631–644.
5. Moore KA, Ema H, Lemischka IR (1997) In vitro maintenance of highly
purified, transplantable hematopoietic stem cells. Blood 89: 4337–4347.
6. Zhang CC, Lodish HF (2008) Cytokines regulating hematopoietic stem cell
function. Curr Opin Hematol 15: 307–311.
7. Weissman IL, Shizuru JA (2008) The origins of the identification and isolation of
hematopoietic stem cells, and their capability to induce donor-specific
transplantation tolerance and treat autoimmune diseases. Blood 112:
3543–3553.
8. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, et al. (2005)
Development of functional human blood and immune systems in NOD/SCID/
IL2 receptor {gamma} chain(null) mice. Blood 106: 1565–1573.
9. Legrand N, Ploss A, Balling R, Becker PD, Borsotti C, et al. (2009) Humanized
mice for modeling human infectious disease: challenges, progress, and outlook.
Cell Host Microbe 6: 5–9.
10. Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational
biomedical research. Nat Rev Immunol 7: 118–130.
11. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, et al. (2004)
Development of a human adaptive immune system in cord blood cell-
transplanted mice. Science 304: 104–107.
12. Zhang CC, Kaba M, Ge G, Xie K, Tong W, et al. (2006) Angiopoietin-like
proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat Med 12:
240–245.
13. Huynh H, Iizuka S, Kaba M, Kirak O, Zheng J, et al. (2008) Insulin-like growth
factor-binding protein 2 secreted by a tumorigenic cell line supports ex vivo
expansion of mouse hematopoietic stem cells. Stem Cells 26: 1628–1635.
14. Zhang CC, Kaba M, Iizuka S, Huynh H, Lodish HF (2008) Angiopoietin-like 5
and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic
stem cells as assayed by NOD/SCID transplantation. Blood 111: 3415–3423.
15. Giassi LJ, Pearson T, Shultz LD, Laning J, Biber K, et al. (2008) Expanded
CD34+ human umbilical cord blood cells generate multiple lymphohematopoi-
etic lineages in NOD-scid IL2rgamma(null) mice. Exp Biol Med (Maywood) 233:
997–1012.
16. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, et al. (2010)
Notch-mediated expansion of human cord blood progenitor cells capable of
rapid myeloid reconstitution. Nat Med 16: 232–236.
17. Ziegler-Heitbrock L (2007) The CD14+ CD16+ blood monocytes: their role in
infection and inflammation. J Leukoc Biol 81: 584–592.
18. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. (1997)
AC133, a novel marker for human hematopoietic stem and progenitor cells.
Blood 90: 5002–5012.
19. Sauvageau G, Humphries RK (2010) Medicine. The blood stem cell Holy Grail?
Science 329: 1291–1292.
20. Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, et al. (2010) Aryl
hydrocarbon receptor antagonists promote the expansion of human hemato-
poietic stem cells. Science 329: 1345–1348.
21. Gluckman E, Rocha V (2009) Cord blood transplantation: state of the art.
Haematologica 94: 451–454.
22. Hayakawa J, Hsieh MM, Uchida N, Phang O, Tisdale JF (2009) Busulfan
produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(-
null) mice. Stem Cells 27: 175–182.
23. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, et al. (2005) Human
lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null
mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174:
6477–6489.
24. Manz MG, Di Santo JP (2009) Renaissance for mouse models of human
hematopoiesis and immunobiology. Nat Immunol 10: 1039–1042.
25. Chen Q, Khoury M, Chen J (2009) Expression of human cytokines dramatically
improves reconstitution of specific human-blood lineage cells in humanized
mice. Proc Natl Acad Sci U S A.
26. Blom B, Spits H (2006) Development of human lymphoid cells. Annu Rev
Immunol 24: 287–320.
27. Wodnar-Filipowicz A (2003) Flt3 ligand: role in control of hematopoietic and
immune functions of the bone marrow. News Physiol Sci 18: 247–251.
Expanded HSCs Efficiently Engraft NSG Mice
PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18382